Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacob Schwartzman

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Surgery Journal (New York, N.Y.)|March 7, 2022
Resident Endoscopy Experience Correlates Poorly with Performance on a Virtual Reality SimulatorKurun Partap S Oberoi, Michael T Scott, Jacob Schwartzman, et al.
The Prostate|May 11, 2013
Immunohistochemical expression of ERG in the molecular epidemiology of fatal prostate cancer studySheila Weinmann, Stephen K Van Den Eeden, Reina Haque, et al.
Oncotarget|January 18, 2018
Integrative molecular network analysis identifies emergent enzalutamide resistance mechanisms in prostate cancerCarly J King, Josha Woodward, Jacob Schwartzman, et al.
Scientific Reports|March 9, 2019
Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancerDaniel J Coleman, Lina Gao, Jacob Schwartzman, et al.
Investigational New Drugs|November 29, 2014
A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancerJoshi J Alumkal, Rachel Slottke, Jacob Schwartzman, et al.
Oncogene|April 19, 2019
BET bromodomain inhibition blocks the function of a critical AR-independent master regulator network in lethal prostate cancerDaniel J Coleman, Lina Gao, Carly J King, et al.
Epigenetics|September 28, 2011
A DNA methylation microarray-based study identifies ERG as a gene commonly methylated in prostate cancerJacob Schwartzman, Solange Mongoue-Tchokote, Angela Gibbs, et al.
Neoplasia (New York, N.Y.)|May 14, 2020
Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4Daniel J Coleman, David A Sampson, Archana Sehrawat, et al.
Oncotarget|June 9, 2016
Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptorDaniel J Coleman, Kathryn Van Hook, Carly J King, et al.
Cancer Discovery|April 29, 2017
Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of <i>BRCA2</i> Reversion Mutations Associated with Resistance to PARP InhibitorsDavid Quigley, Joshi J Alumkal, Alexander W Wyatt, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Surgery Journal (New York, N.Y.)|March 7, 2022
Resident Endoscopy Experience Correlates Poorly with Performance on a Virtual Reality SimulatorKurun Partap S Oberoi, Michael T Scott, Jacob Schwartzman, et al.
The Prostate|May 11, 2013
Immunohistochemical expression of ERG in the molecular epidemiology of fatal prostate cancer studySheila Weinmann, Stephen K Van Den Eeden, Reina Haque, et al.
Oncotarget|January 18, 2018
Integrative molecular network analysis identifies emergent enzalutamide resistance mechanisms in prostate cancerCarly J King, Josha Woodward, Jacob Schwartzman, et al.
Scientific Reports|March 9, 2019
Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancerDaniel J Coleman, Lina Gao, Jacob Schwartzman, et al.
Investigational New Drugs|November 29, 2014
A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancerJoshi J Alumkal, Rachel Slottke, Jacob Schwartzman, et al.
Oncogene|April 19, 2019
BET bromodomain inhibition blocks the function of a critical AR-independent master regulator network in lethal prostate cancerDaniel J Coleman, Lina Gao, Carly J King, et al.
Epigenetics|September 28, 2011
A DNA methylation microarray-based study identifies ERG as a gene commonly methylated in prostate cancerJacob Schwartzman, Solange Mongoue-Tchokote, Angela Gibbs, et al.
Neoplasia (New York, N.Y.)|May 14, 2020
Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4Daniel J Coleman, David A Sampson, Archana Sehrawat, et al.
Oncotarget|June 9, 2016
Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptorDaniel J Coleman, Kathryn Van Hook, Carly J King, et al.
Cancer Discovery|April 29, 2017
Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of <i>BRCA2</i> Reversion Mutations Associated with Resistance to PARP InhibitorsDavid Quigley, Joshi J Alumkal, Alexander W Wyatt, et al.
Pageof 3